Clinical Trials

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT06638931 2026-04-15

ANTARES

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

28 enrolled

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT07529613 2026-04-14

T-DXd_HER2Low

Phase 1/2 Completed

30 enrolled

Stomach Neoplasms

NCT06346197 2026-04-08

CIME

132 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT05677490 2026-04-07

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Adenocarcinoma Of Esophagus

NCT05480384 2026-04-01

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

1 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04963283 2026-03-31

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

48 enrolled

Phase 1 Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07075120 2026-03-31

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Carcinoma, Hepatocellular

NCT04503694 2026-03-27

REGINA

72 enrolled

Phase 1 Active not recruiting

Rectal Neoplasms

NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

32 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Microsatellite-stable Colorectal Cancer

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Phase 1 Completed

5 enrolled

Carcinoma, Hepatocellular

NCT05187182 2026-03-18

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

42 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT04457284 2026-03-13

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

18 enrolled

Colorectal Adenocarcinoma

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

197 enrolled

Colorectal Neoplasms

NCT02829918 2026-03-11

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Phase 2 Completed

54 enrolled 11 charts

Biliary Tract Neoplasms, Digestive System Diseases

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Phase 1/2 Recruiting

Carcinoma, Hepatocellular

NCT03026140 2026-03-05

NICHE

353 enrolled

Colonic Neoplasms

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

39 enrolled

EndocrineGastrointestinalThoracic

Esophageal Neoplasms

NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Phase 1/2 Terminated

13 enrolled

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Completed

34 enrolled 13 charts

Phase 2 Not yet recruiting

Biliary Tract Neoplasms

NCT07403877 2026-02-11

TORCH-OPTIMA

114 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT03712943 2026-02-09

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Phase 1 Completed

52 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT07376707 2026-01-29

TGI5

DermatologicGastrointestinalThoracic

194 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

39 enrolled

Phase 2 Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07369791 2026-01-28

NOBLE

76 enrolled

Phase 1/2 Active not recruiting

Advanced Biliary Tract Cancer(BTC)

NCT04599140 2026-01-22

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

51 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

12 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03104439 2026-01-12

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

84 enrolled

Pancreatic Neoplasms

NCT03921684 2026-01-05

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

29 enrolled

Rectal Neoplasms

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled

Colonic Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT03610711 2025-12-22

REACTION

21 enrolled

Gastroesophageal Cancer

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

43 enrolled

Pancreatic Neoplasms

NCT05802056 2025-12-19

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Phase 1 Active not recruiting

Stomach Neoplasms

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

31 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

76 enrolled

Pancreatic Neoplasms

NCT03767582 2025-12-03

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Phase 1/2 Completed

46 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

27 enrolled

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

56 enrolled

Fibrolamellar hepatocellular carcinoma

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Pancreatic Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled